Preparation, Characterization, and In Vivo Evaluation of an Oral Triptolide Nanomatrix System for Rheumatoid...

Area of Science:

• Pharmacology
• Materials Science
• Drug Delivery

Background:

• Triptolide (TP) possesses potent anti-inflammatory properties but is limited by poor solubility and systemic toxicity.
• Uncontrolled oral absorption contributes to Triptolide's toxicity.
• An established oral nanomatrix system enhances dissolution and modulates drug absorption.

Purpose of the Study:

• To develop and evaluate a Triptolide nanomatrix system using Sylysia 350 and Eudragit® L100.
• To modulate Triptolide's dissolution profile and improve its therapeutic potential.
• To assess the efficacy and safety of the Triptolide nanomatrix in a rheumatoid arthritis model.

Main Methods:

• Preparation of a Triptolide nanomatrix system with Sylysia 350 and Eudragit® L100.
• Evaluation through in vitro dissolution, physicochemical characterization, and in vivo pharmacokinetic studies.
• Assessment of anti-inflammatory efficacy and safety in a rat model of rheumatoid arthritis.

Main Results:

• The Triptolide nanomatrix system significantly increased drug dissolution, particularly in pH 6.8 medium.
• Enhanced oral bioavailability was observed compared to free Triptolide.
• No significant toxicity was detected with the nanomatrix formulation.

Conclusions:

• A simple oral nanomatrix system for Triptolide was successfully developed.
• The system demonstrated enhanced anti-inflammatory efficacy without observable toxicity.
• This approach offers a potential strategy for the clinical advancement of Triptolide products.